Table 2 Responses by prior lines of therapy

From: Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

 

1 Prior line

⩾2 Prior lines

 

Kd (n=232)

Vd (n=232)

Kd (n=232)

Vd (n=233)

Best overall response, n (%)

 Stringent complete response

6 (2.6)

6 (2.6)

2 (0.9)

3 (1.3)

 Complete response

21 (9.1)

12 (5.2)

29 (12.5)

8 (3.4)

 Very good partial response

117 (50.4)

53 (22.8)

77 (33.2)

51 (21.9)

 Partial response

46 (19.8)

80 (34.5)

58 (25.0)

77 (33.0)

Overall response rate, % (95% CI)

81.9 (76.3–86.6)

65.5 (59.0–71.6)

72.0 (65.7–77.7)

59.7 (53.1–66.0)

Median duration of response, months (95% CI)

21.3 (17.6–NE)

14.1 (8.6–NE)

NE (13.9–NE)

10.3 (9.0–12.2)

  1. Abbreviations: CI, confidence interval; Kd, carfilzomib and dexamethasone; NE, not estimable; Vd, bortezomib and dexamethasone.
Back to article page